Scorpius Holdings Inc. · OTC:SCPX
Scorpius — Heat Biologics — Investor Presentation (May 2020)
20 slides from Scorpius's investor presentation, May 29, 2020
Slide 1: Corporate Presentation May 2020
Heat Biologics NASDAQ: HTBX CORPORATE PRESENTATION MAY 2020 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements’’ within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended . In some cases, these forward - looking statements can be identified by the use of fo
Slide 3: Snapshot of Heat Biologics
Snapshot of Heat Biologics (Nasdaq: HTBX) • US - based biopharmaceutical company developing potential first - in - class immunotherapy products • HS - 110, an “off - the - shelf” cell - based immunotherapy product that has the potential to improve PD(L) - 1 therapy - Ongoing Phase 2 program demonstr
Slide 4: Product Pipeline
Product Pipeline 4 CTA = cancer testis antigen; NSCLC = Non - small cell lung cancer
Slide 5: HS-110 Overview
HS - 110 Overview • HS - 110 is a Phase 2 cell - based immunotherapy administered in combination with PD - (L)1 therapies to improve clinical outcomes for NSCLC patients - Allogeneic cells with engineered gp96 to present multiple cancer testis antigens - Selectively activate CD8+ “killer” T cells -
Slide 6: Heat Biologics' gp96 Platform Activating the Immune System
H eat Biologics’ gp96 Platform Activating the Immune System • Function of heat shock protein gp96: - Potent mucosal adaptive memory inducer - Chaperones antigens (pathogens or tumor) to the immune system - Activates B cell response and drives antigen - specific CD4 and CD8 T cel l activation • platf
Slide 7: Heat Biologics' gp96 Platform Activating the Immune System
H eat Biologics’ gp96 Platform Activating the Immune System • Function of heat shock protein gp96: - Potent mucosal adaptive memory inducer - Chaperones antigens (pathogens or tumor) to the immune system - Activates B cell response and drives antigen - specific CD4 and CD8 T cel l activation • Key f
Slide 8: gp96 Platform Applications in Oncology: HS-110
H eat Biologics’ gp96 Platform Applications in Oncology: HS - 110 2 4 6 8 10 12 0 5 10 15 20 Day Post Transfer / Treatment P e r c e n t a g e ( % ) P OT-2/ CD4+ T cells OT-1/ CD8+ T cells Heat Biologics Internal Data 8 ᬚ Secretion of gp96 - Ig carrying tumor specific proteins represented on the pat
Slide 9: HS-110 Cohort A and Cohort B Phase 2 Results
Cohort A: 2+ line Checkpoint Inhibitor (CPI) naïve patients Cohort B: 2+ line patients that progressed after CPI Δ Heat Biologics Cohort A interim results as of January 2020 data cut. Median progression free survival (PFS) and median overal l s urvival (OS) are reported here. Median follow - up time
Slide 10: OS by Injection Site Reaction (ISR)
OS by Injection Site Reaction (ISR) In Both Cohort A and Cohort B, Significantly Improved OS in Patients who Experienced Dermal Injection Site Reaction ISR = Yes refers to patients who experienced at least one injection site reaction at any time during treatment 10
Slide 11: Product Pipeline
Product Pipeline 11 CTA = cancer testis antigen; NSCLC = Non - small cell lung cancer
Slide 12: HS-130 Overview
HS - 130 Overview • HS - 130 is the first allogeneic, off - the - shelf, cell therapy approach utilizing OX40 - mediated co - stimulation to enhance activation of dormant immune signal - Leverage HS - 110 clinical experience and manufacturing know - how - Addition of OX40L fusion protein to extend a
Slide 13: Product Pipeline
Product Pipeline 13 CTA = cancer testis antigen; NSCLC = Non - small cell lung cancer
Slide 14: gp96 Platform for Infectious Disease
gp96 Platform for Infectious Disease • gp96 platform demonstrated efficacy in multiple infectious diseases - Significant mucosal protection against simian immunodeficiency virus (SIV) in monkey - Induction of Zika - specific CD8 T cells in mouse - No pathological changes in placenta or fetus - Eleva
Slide 15: Key Differentiation of gp96 Platform
Key Differentiation of gp96 Platform • Heat’s gp96 platform - based products evaluated in 300+ patients to date - HS - 110 (Phase 2) demonstrated favorable safety profile and clinical efficacy in combination with PD - 1 inhibitors for treatment of NSCLC • Potential first - in - class for infectious
Slide 16: Heat Biologics' COVID-19 Vaccine Program
Heat Biologics’ COVID - 19 Vaccine Program • Leverages our proprietary gp96 platform to effectively deliver multiple SARS - CoV - 2 antigens to activate the immune system • Designed to elicit long - lasting immune response against SARS - CoV - 2 virus • We plan to collaborate with companies, researc
Slide 17: Product Pipeline
Product Pipeline 17 CTA = cancer testis antigen; NSCLC = Non - small cell lung cancer
Slide 18: PTX-35 Overview
PTX - 35 Overview • Potential first - in - class T cell co - stimulator targeting TNFRSF25, with preferential specificity to generate “memory” CD8+ T cells - IND clearance and first patient dosing expected by end of Q2 2020 • Broad market potential - Efficacy demonstrated in multiple preclinical in
Slide 19: Snapshot of Heat Biologics
Snapshot of Heat Biologics (Nasdaq: HTBX) • US - based biopharmaceutical company developing potential first - in - class immunotherapy products • HS - 110, an “off - the - shelf” cell - based immunotherapy product that has the potential to improve PD(L) - 1 therapy - Ongoing Phase 2 program demonstr
Slide 20: Heat Biologics
Heat Biologics NASDAQ: HTBX 20